Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized Irinotecan/Paclitaxel vs Irinotecan/Gemcitabine in advanced NSCLC
jRCT1080220109Phase 2
- Sponsor
- Yakult Honsha
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yakult Honsha.
02
Drugs
irinotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080220109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220109.